Lantheus (NASDAQ:LNTH) Stock Rating Lowered by ValuEngine

Lantheus (NASDAQ:LNTH) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, ValuEngine reports.

A number of other research analysts have also recently commented on the stock. BidaskClub cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 11th. Zacks Investment Research cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, April 24th.

NASDAQ LNTH remained flat at $$22.49 during trading hours on Thursday. 428,304 shares of the company’s stock were exchanged, compared to its average volume of 438,680. The stock has a fifty day moving average of $26.98. Lantheus has a 52 week low of $12.59 and a 52 week high of $29.80. The company has a debt-to-equity ratio of 2.05, a current ratio of 2.62 and a quick ratio of 2.01. The company has a market capitalization of $873.06 million, a P/E ratio of 23.93, a PEG ratio of 1.79 and a beta of 1.48.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.27. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The company had revenue of $85.70 million for the quarter, compared to analysts’ expectations of $88.72 million. During the same quarter in the prior year, the company posted $0.25 earnings per share. Lantheus’s revenue for the quarter was up .1% compared to the same quarter last year. On average, sell-side analysts expect that Lantheus will post 1.06 earnings per share for the current fiscal year.

In other news, Director Brian A. Markison sold 5,000 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $28.41, for a total transaction of $142,050.00. Following the sale, the director now owns 32,467 shares of the company’s stock, valued at $922,387.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Cesare Orlandi sold 35,586 shares of the stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $28.17, for a total transaction of $1,002,457.62. Following the sale, the insider now directly owns 75,155 shares in the company, valued at approximately $2,117,116.35. The disclosure for this sale can be found here. Insiders sold 146,187 shares of company stock worth $3,853,913 in the last ninety days. 2.60% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Mason Street Advisors LLC lifted its position in shares of Lantheus by 3.6% during the first quarter. Mason Street Advisors LLC now owns 12,380 shares of the medical equipment provider’s stock worth $303,000 after purchasing an additional 435 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Lantheus by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 26,714 shares of the medical equipment provider’s stock worth $418,000 after purchasing an additional 587 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Lantheus by 0.9% during the fourth quarter. Legal & General Group Plc now owns 82,403 shares of the medical equipment provider’s stock worth $1,272,000 after purchasing an additional 721 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Lantheus by 1.3% during the second quarter. Arizona State Retirement System now owns 60,218 shares of the medical equipment provider’s stock worth $1,704,000 after purchasing an additional 752 shares in the last quarter. Finally, TD Asset Management Inc. lifted its position in shares of Lantheus by 1.4% during the second quarter. TD Asset Management Inc. now owns 63,009 shares of the medical equipment provider’s stock worth $1,783,000 after purchasing an additional 900 shares in the last quarter. 91.50% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: What is a recession?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.